

## Systematic Review of CVD Risk Assessment Tools

### Full Text Review Form

First Author, Year: \_\_\_\_\_ Ref ID # \_\_\_\_\_ Abstractor Initials: \_\_\_\_\_

<p>1. Relevant to SER topic</p> <p><b>If NO:</b></p> <ul style="list-style-type: none"> <li>a. Post-PCI_____</li> <li>b. Post-CABG_____</li> <li>c. Diagnostic_____</li> <li>d. Prognostic_____</li> <li>e. Etiologic_____</li> <li>f. Not a risk tool_____</li> <li>g. Other_____</li> </ul>	Yes	No		
<p>2. Attempts internal or external validation (evaluation of risk model)</p> <p><b>If YES:</b></p> <ul style="list-style-type: none"> <li>a. ROC analysis_____</li> <li>b. O/E ratios_____</li> <li>c. Calibration Plots_____</li> <li>d. Hosmer-Lemeshow_____</li> <li>e. Other_____</li> </ul>	Yes	No		
<p>3. Published in English</p>	Yes	No		
<p>4. Original research (exclude reviews, editorials, commentaries, letters to editor, etc.)</p>	Yes	No		
<p>5. Eligible Study types</p> <ul style="list-style-type: none"> <li>a. Randomized controlled trials_____</li> <li>b. Controlled clinical trials_____</li> <li>c. Cohorts_____</li> <li>d. Case-series_____</li> </ul>	Yes	No		
<p>6. Reports relevant outcomes:</p> <ul style="list-style-type: none"> <li>a. Coronary Artery Disease (non fatal and fatal MI and sudden coronary heart disease death)</li> <li>b. Cerebrovascular stroke (thrombotic/hemorrhagic)</li> <li>c. Combination of a. and b.</li> </ul>	Yes	No		
<p>7. Study size <math>\geq 200</math></p> <p><b>If NO:</b> State study size_____</p>	Yes	No		
<p>8. Study population is asymptomatic for CVD</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> <p><b>Exclude:</b></p> <p>MI CAD CABG Stroke Unstable Angina Stable Angina</p> </td> <td style="width: 50%; vertical-align: top;"> <p><b>Include:</b></p> <p>PAD LEAD Hypertension Renal Disease Metabolic Syndrome</p> </td> </tr> </table> <p><b>If NO:</b> State % symptomatic_____%</p>	<p><b>Exclude:</b></p> <p>MI CAD CABG Stroke Unstable Angina Stable Angina</p>	<p><b>Include:</b></p> <p>PAD LEAD Hypertension Renal Disease Metabolic Syndrome</p>	Yes	No
<p><b>Exclude:</b></p> <p>MI CAD CABG Stroke Unstable Angina Stable Angina</p>	<p><b>Include:</b></p> <p>PAD LEAD Hypertension Renal Disease Metabolic Syndrome</p>			

9. Study population is adults aged $\geq 18$ years old	Yes	No
10. Study conducted in the United States	Yes	No
<b>If NO:</b> State country _____		
11. Length of Follow-Up _____		

**Retain for:**

\_\_\_\_ **BACKGROUND/DISCUSSION**

\_\_\_\_ **REVIEW OF REFERENCES**

\_\_\_\_ **Other** \_\_\_\_\_